California State Teachers Retirement System Lowers Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

California State Teachers Retirement System decreased its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 1.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,206 shares of the company’s stock after selling 1,844 shares during the quarter. California State Teachers Retirement System owned 0.07% of Hims & Hers Health worth $1,490,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Point72 Middle East FZE bought a new position in shares of Hims & Hers Health during the fourth quarter valued at about $29,000. Captrust Financial Advisors raised its holdings in Hims & Hers Health by 1,827.4% in the 1st quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock worth $36,000 after purchasing an additional 6,414 shares in the last quarter. CWM LLC purchased a new stake in shares of Hims & Hers Health in the 1st quarter worth about $41,000. Tower Research Capital LLC TRC boosted its stake in shares of Hims & Hers Health by 70.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 9,538 shares of the company’s stock valued at $54,000 after purchasing an additional 3,933 shares in the last quarter. Finally, PFS Investments Inc. purchased a new position in shares of Hims & Hers Health during the fourth quarter valued at about $66,000. 61.45% of the stock is owned by institutional investors.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $6.94 on Thursday. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -31.55 and a beta of 0.48. The stock has a fifty day simple moving average of $8.07 and a two-hundred day simple moving average of $9.28. Hims & Hers Health, Inc. has a 12 month low of $4.01 and a 12 month high of $12.34.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 7th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.03. The firm had revenue of $207.91 million for the quarter, compared to analysts’ expectations of $204.95 million. Hims & Hers Health had a negative net margin of 6.61% and a negative return on equity of 14.97%. The business’s quarterly revenue was up 83.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.10) EPS. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post -0.15 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, COO Melissa Baird sold 9,133 shares of the company’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $8.89, for a total value of $81,192.37. Following the completion of the sale, the chief operating officer now directly owns 426,412 shares in the company, valued at approximately $3,790,802.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, COO Melissa Baird sold 9,133 shares of Hims & Hers Health stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $8.89, for a total transaction of $81,192.37. Following the transaction, the chief operating officer now directly owns 426,412 shares of the company’s stock, valued at approximately $3,790,802.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 6,698 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $6.92, for a total transaction of $46,350.16. Following the completion of the sale, the chief financial officer now directly owns 125,016 shares of the company’s stock, valued at $865,110.72. The disclosure for this sale can be found here. Insiders have sold 332,170 shares of company stock worth $2,883,416 in the last 90 days. 31.63% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Bank of America lifted their price objective on Hims & Hers Health from $13.50 to $15.00 in a research report on Tuesday, May 9th. Piper Sandler reduced their price target on Hims & Hers Health from $11.00 to $10.00 in a research note on Tuesday, August 8th. TD Cowen began coverage on Hims & Hers Health in a research report on Friday, July 28th. They set an “outperform” rating and a $11.00 price objective for the company. Truist Financial dropped their target price on shares of Hims & Hers Health from $12.00 to $10.00 and set a “hold” rating on the stock in a report on Wednesday, August 9th. Finally, Tigress Financial increased their price target on shares of Hims & Hers Health from $12.00 to $14.00 in a research note on Thursday, June 15th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $11.75.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.